Precision IBD, Inc. announced the appointment of Mark C. McKenna as the company's chief executive officer, and the completion of the company's name change to Prometheus Biosciences, Inc. Mr. McKenna succeeds Precision IBD's current CEO Scott Glenn, who co-founded Precision IBD and over a dozen successful biotech companies. Glenn will continue to serve as an active member of the board and advisor to the new CEO.